Profusa, Inc. - Common Stock (PFSA)

BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all proposals presented at the Company’s 2026 Annual Meeting of Shareholders held on June 23, 2026. 

BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee® Oxygen Platform.

BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a leading digital health company pioneering next-generation biosensing technologies, today issued the following letter from Chairman and Chief Executive Officer Ben Hwang, Ph.D., to shareholders in advance of the Company's 2026 Annual Meeting of Shareholders scheduled for June 23, 2026.

BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) --  Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces  that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market. 

BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company’s request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The Company’s continued listing on Nasdaq is subject to the Company’s satisfaction of certain interim milestones and, ultimately, the Company’s compliance with the bid price and stockholders’ equity requirements for continued listing on the Capital Market tier by July 6, 2026.

Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.